Louisiana Health Service & Indemnity Company

Louisiana Health Service & Indemnity Company — doing business as Blue Cross and Blue Shield of Louisiana (rebranded "Louisiana Blue") — is a not-for-profit mutual health insurer headquartered at 5525 Reitz Avenue, Baton Rouge, Louisiana. It was founded in 1934 in New Orleans as the Hospital Service Association of New Orleans, formed by six area hospitals. It is an independent licensee of the Blue Cross and Blue Shield Association and remains privately held and Louisiana-owned; a proposed $2.5 billion acquisition by Elevance Health was announced in January 2023 but withdrawn in February 2024 amid regulatory and stakeholder opposition. Public sources put employment at roughly 2,500–3,000 and membership at about 1.9 million Louisianians (approximately one in three residents).

Products / services. The company sells and administers health insurance: individual and family plans, employer/group coverage, Medicare Advantage and Medicare supplement plans, dental and vision, and prescription drug coverage. It also provides third-party administrative services for self-funded employer health plans. Its subsidiary HMO Louisiana, Inc. is a licensed health maintenance organization. It is an operating company with no patent portfolio of its own in these records.

Patent-litigation posture. The case data shows 1 tracked matter, as plaintiff only and zero as defendant — consistent with an operating company using the courts offensively, not a non-practicing entity. The single suit is an antitrust/patent-abuse class action rather than a patent-infringement claim, and it was filed in the Southern District of New York, not a plaintiff-friendly patent venue such as the Eastern District of Texas.

Notable case. Louisiana Health Service & Indemnity Company v. Celgene Corporation (S.D.N.Y., 1:23-cv-07871-ER, filed 2023-09-05), brought with HMO Louisiana and an individual plaintiff against Celgene, Bristol Myers Squibb, and two individuals. Plaintiffs allege Sherman Act monopolization of the market for pomalidomide (Pomalyst), including Walker Process fraud on the U.S. Patent and Trademark Office, sham patent litigation against generic manufacturers, and reverse-payment settlements delaying generic entry. The court granted defendants' motions to dismiss in April 2025; plaintiffs sought leave to file a second amended complaint.